WB-MRI may be suggested as an alternative for the expected diagnosis of polymetastatic disease based on clinical and biological data, in the case of equivocal results not only from BS or CT but also from PSMA-PET/CT (numerous false positives and false negatives due to lack of PSMA expression by cancer cells), in advanced disease (castration-resistant cancer) prior to new therapy to assess disease response (including Lutetium 177-PSMA treatment), and in centers lacking PSMA-PET/CT [44]. This evidence concerns the gene FOLH1 and cancer.